Defeat Duchenne Canada is committed to bringing the latest in Duchenne muscular dystrophy research and drug development to you – our Canadian Duchenne community. Complete the registration form below to receive the link.

Webinar Series: Industry Partner Update from Avidity Biosciences

Avidity Biosciences – EXPLORE44-OLE® Topline and Functional Data Presentation with Elizabeth (Lisa) Ackermann, Avidity’s Senior Vice President of Clinical Development

The company plans to share topline and functional data from their EXPLORE44-OLE® clinical trial. Their investigational therapy, delpacibart zotadirsen (abbreviated as del-zota), is in development for boys and men with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44).